Latest Conference Coverage

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other.

A pair of datasets from the phase 3b CASTING study of ocrelizumab (Ocrevus; Genentech) suggest that patients treated with the agent experienced high rates of no evidence of disease activity status regardless of prior DMT exposure.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed the results of a phase 2 core and extension study of ponesimod in patients with relapsing-remitting multiple sclerosis.

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers explained how social prescribing can play a key role in the prevention of social isolation.

Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.

The director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine gave his perspective on the interim findings of a long-term safety study of apomorphine sublingual film.

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.

The neurologist at Lenox Hill Hospital detailed the findings of his observational study that looked at patterns of COVID-19 infections in patients with multiple sclerosis.

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.

The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.

The percentage of patients reporting no OFF time and no impact of OFF on daily function more than doubled by the first on-treatment visit in this open-label trial.

The director of the VA Southwest Parkinson’s Disease Research, Education and Clinical Centers discussed how loneliness can impact Parkinson disease severity and how holistic approaches to care may help.

Data show that higher CSF tau levels at diagnosis correlated with worse disability independent of age, though no such associations were identified with amyloid-beta.

Benefits of levodopa-carbidopa intestinal gel lasted throughout the day and showed greater benefits of continuous dopaminergic stimulation in disease control than immediate release oral capsules.

The COMT inhibitor, which was approved in April 2020, may be a worthwhile option as a first-line adjunctive treatment for those with Parkinson disease with motor fluctuations.

Improvement in dyskinesia occurred after 2 weeks of treatment with levodopa-carbidopa intestinal gel and was sustained throughout the study.

No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.

Supporting patient activation of their knowledge, skill, and confidence in managing their health may empower patients in times of stress.

Three-year data from a phase 1 study of Voyager Therapeutics’ VY-AADC01 suggest it is safe and offers potential benefits for patients with Parkinson disease.

Scores reflective of tremor in each body part and task performance improved by 71% in patients from baseline before first thalamotomy to 6 months after second thalamotomy.

After 3 months of treatment, an overwhelming number of clinicians and patients preferred directional over omnidirectional DBS.

Results from a phase 2 pilot study of nabilone in Parkinson disease suggest that the synthetic cannabinoid might hold therapeutic potential for nonmotor symptoms.

Treatment-naïve patients showed consistent results with the overall study population that was observed in the ASCLEPIOS I and II trials.

Patients with relapsing multiple sclerosis and high levels of fatigue were less likely to be employed full-time than those with MS with low fatigue.

Despite previous literature documenting cardiovascular disease comorbidity in patients with narcolepsy, pitolisant treatment did not demonstrate any cardiac safety signals.